Intrinsic Value of S&P & Nasdaq Contact Us

SCYNEXIS, Inc. SCYX NASDAQ

NASDAQ Global Market • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
65/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

SCYNEXIS, Inc. (SCYX) — Analyst outlook / Analyst consensus target is. Based on 14 analyst ratings, the consensus is bullish — 13 Buy, 1 Hold.

Analysts estimate Earnings Per Share (EPS) of $-0.43 and revenue of $0.01B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-0.44 vs est $-0.43 (missed -1.5%). 2025: actual $-0.17 vs est $-0.31 (beat +45.7%). Analyst accuracy: 57%.

SCYX Analyst Ratings

Buy
14
Ratings
13 Buy
1 Hold
Based on 14 analysts giving stock ratings to SCYNEXIS, Inc. in the past 3 months
Rating breakdown
Buy
13 93%
Hold
1 7%
93%
Buy
13 analysts
7%
Hold
1 analysts
0%
Sell
0 analysts

EPS Estimates — SCYX

57%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024 Actual –$0.44 vs Est –$0.43 ▼ 1.5% off
2025 Actual –$0.17 vs Est –$0.31 ▲ 84.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.

Revenue Estimates — SCYX

0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024 Actual $0.004B vs Est $0.013B ▼ 245.9% off
2025 Actual $0.021B vs Est $0.010B ▲ 51.7% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message